Andersen Shemme, MD
Epilepsy · Muskegon, MINPI 1861986481
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $760 and has fallen 83.6% since, to $125 in 2021.
Across 15 payments — averaging $100.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$250
- Greenwich Biosciences, Inc.$137
- Aquestive Therapeutics, Inc.$125
- Kyowa Kirin, Inc.$125
- Neurocrine Biosciences, Inc.$125
- Acadia Pharmaceuticals Inc$123
- plus $628 from 6 others
What the payments were for
- Food & beverage$1,514100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 2 | $250 |
| Greenwich Biosciences, Inc. | 1 | $137 |
| Aquestive Therapeutics, Inc. | 1 | $125 |
| Kyowa Kirin, Inc. | 1 | $125 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Acadia Pharmaceuticals Inc | 1 | $123 |
| Genentech USA, Inc. | 1 | $122 |
| SK Life Science, Inc. | 1 | $122 |
| Amgen | 1 | $120 |
| Teva Pharmaceuticals USA, Inc. | 1 | $117 |
| Pfizer | 2 | $105 |
| AstraZeneca | 2 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,514 in reported general payments places this provider in the 65th percentile of 30 epilepsy providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 17 | $31,542 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $7,933 |
| Lacosamide | 60 | $2,793 |
| Levetiracetam | 48 | $1,337 |
| Oxcarbazepine | 15 | $592 |
| Propranolol Hcl | 15 | $347 |
| Lamotrigine | 15 | $314 |
| Gabapentin | 19 | $232 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Muskegon
- David BurdetteGrand Rapids$1.4M
- Evan TankGrand Rapids$28K
- Ammar KhederGrand Rapids$12K
- Barbara SwartzWyoming$10K
- Ayman AlboudiDetroit$5K
- Samuel TermanAnn Arbor$4K
- Charles AsburyGrand Rapids$2K
- Rachel FabrisGrand Rapids$2K
- David OrtizGrand Rapids$2K
- Giulia BenedettiAnn Arbor$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.